advertisement

WGA Rescources

Abstract #51713 Published in IGR 14-4

Effect of Latanoprost on Central Corneal Thickness in Unilateral Normal-Tension Glaucoma

You JY; Cho BJ
Journal of Ocular Pharmacology and Therapeutics 2013; 29: 335-338


PURPOSE: To evaluate the effect of latanoprost on central corneal thickness (CCT) in patients with unilateral normal-tension glaucoma (NTG). METHODS: A total of 38 patients, with unilateral NTG, who were being followed in our glaucoma clinic and were receiving 0.005% latanoprost monotherapy over 24 months, were included. The data were collected, retrospectively, with reviewing of the charts. The mean CCT and the CCT reduction from the baseline were assessed before the treatment, and 3, 6, 9, 12, and 24 months after the initiation of the treatment. An unaffected eye was also evaluated for the control group. All the measurements were performed with a commercially available ultrasound pachymeter. RESULTS: There were no significant differences between the eyes for the baseline intraocular pressure and CCT. The mean CCT trend was decreased, except at 9 months after the treatment in the latanoprost group (affected eye), but only statistically significant after 24 months of treatment by using paired-sample t-test [544.6±38.4 vs. 540.3±37.8 μm (P=0.013)]. There was no statistically significant changes of CCT between the groups with repeated measures analysis of variance (P=0.635). CONCLUSION: Topical therapy with latanoprost may decrease the CCT, over a period of 24 months, in patients with NTG. These data should be taken into consideration in a long-standing latanoprost treatment of NTG.

Department of Ophthalmology, Konkuk University Medical Center, Konkuk University School of Medicine , Seoul, Republic of Korea.

Full article

Classification:

11.4 Prostaglandins (Part of: 11 Medical treatment)
2.2 Cornea (Part of: 2 Anatomical structures in glaucoma)
9.2.4 Normal pressure glaucoma (Part of: 9 Clinical forms of glaucomas > 9.2 Primary open angle glaucomas)



Issue 14-4

Change Issue


advertisement

Oculus